Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
Latest Hotspot
8 min read
Alzheimer's Disease Indication Strategy Report 2026: Amyloid-β, Tau, Trials and $2.2B Deal
17 July 2026
Alzheimer's Disease Indication Strategy Report 2026: Amyloid-β, Tau, Trials and $2.2B Deal uses PatSnap MCP evidence to evaluate disease burden, target rationale, clinical competition, transaction signals, unmet need and market attractiveness for one indication only.
Latest Hotspot
8 min read
Non-Small Cell Lung Cancer Indication Strategy Report 2026: EGFR, KRAS, Trials and Deal Outlook
17 July 2026
A 2026 NSCLC indication strategy report covering epidemiology, EGFR and KRAS biology, Phase 3 competition, deal activity and R&D positioning.
8 min read
TRPM4 Target Evaluation Report 2026: Biology, Validation, Competition, IP, and R&D Strategy
17 July 2026
A visual target evaluation report for TRPM4, generated in a PatSnap Life Sciences MCP-style workflow covering biology, validation evidence, clinical competition, IP signals, and R&D strategy.
Latest Hotspot
8 min read
Inflammatory Bowel Disease Indication Strategy Report 2026: Unmet Need, Competition, Targets and Market Attractiveness
17 July 2026
Inflammatory Bowel Disease 2026 strategy: unmet need, clinical competition, target mechanisms and 2023–2026 deal signals from PatSnap MCP workflows.
Latest Hotspot
8 min read
MASH Indication Strategy Report 2026: Epidemiology, Target Biology, Clinical Competition and Deal Outlook
17 July 2026
A 2026 MASH indication strategy report covering disease burden, THR-β and FGF21 biology, clinical competition, deal activity and R&D positioning.
8 min read
TRPM2 Target Evaluation Report 2026: Biology, Validation, Competition, IP, and R&D Strategy
17 July 2026
A visual target evaluation report for TRPM2, generated in a PatSnap Life Sciences MCP-style workflow covering biology, validation evidence, clinical competition, IP signals, and R&D strategy.
Latest Hotspot
8 min read
Obesity Indication Strategy Report 2026: Unmet Need, Competition, Targets and Market Attractiveness
17 July 2026
Obesity 2026 strategy: unmet need, clinical competition, target mechanisms and 2023–2026 deal signals from PatSnap MCP workflows.
8 min read
TRPC6 Target Evaluation Report 2026: Biology, Validation, Competition, IP, and R&D Strategy
17 July 2026
A visual target evaluation report for TRPC6, generated in a PatSnap Life Sciences MCP-style workflow covering biology, validation evidence, clinical competition, IP signals, and R&D strategy.
8 min read
TRPC5 Target Evaluation Report 2026: Biology, Validation, Competition, IP, and R&D Strategy
17 July 2026
A visual target evaluation report for TRPC5, generated in a PatSnap Life Sciences MCP-style workflow covering biology, validation evidence, clinical competition, IP signals, and R&D strategy.
8 min read
TRPC3 Target Evaluation Report 2026: Biology, Validation, Competition, IP, and R&D Strategy
17 July 2026
A visual target evaluation report for TRPC3, generated in a PatSnap Life Sciences MCP-style workflow covering biology, validation evidence, clinical competition, IP signals, and R&D strategy.
Latest Hotspot
8 min read
Repare Therapeutics Company BD Opportunity Scan Report 2026: Pipeline, Deals, Partnering Shortlist, and Outreach Priorities
17 July 2026
Repare Therapeutics 2026 BD opportunity scan: pipeline assets, transaction precedents, financial signals, IP-risk flags, and a prioritized partnering shortlist.
Latest Hotspot
8 min read
Zentalis Pharmaceuticals Company BD Opportunity Scan Report 2026: Pipeline, Deals, Partnering Shortlist, and Outreach Priorities
17 July 2026
Zentalis Pharmaceuticals 2026 BD opportunity scan: pipeline assets, transaction precedents, financial signals, IP-risk flags, and a prioritized partnering shortlist.